Literature DB >> 17956200

Apomorphine therapy in Parkinson's disease: a review.

Ihtsham Ul Haq1, Peter A Lewitt, Hubert H Fernandez.   

Abstract

Motor fluctuations are common and distressing for patients with advanced Parkinson's disease. Subcutaneous apomorphine injections can be an extremely valuable adjunctive therapy. In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' states in Parkinson's disease, with a focus on intermittent subcutaneous administration.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17956200     DOI： 10.1517/14656566.8.16.2799

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  10 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

Authors:  Liming Luan; Feng Ding; Yi Ai; Anders Andersen; Peter Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

3.  Medical management of Parkinson's disease.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2008-10

Review 4.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

Review 5.  Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Glenardi Glenardi; Tutwuri Handayani; Jimmy Barus; Ghea Mangkuliguna
Journal:  Neurol Clin Pract       Date:  2022-04

Review 6.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep

Review 7.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

8.  Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.

Authors:  Marianne Luinstra; Wijnand Rutgers; Teus van Laar; Floris Grasmeijer; Anja Begeman; Valmira Isufi; Luc Steenhuis; Paul Hagedoorn; Anne de Boer; Henderik W Frijlink
Journal:  Ther Adv Chronic Dis       Date:  2019-06-21       Impact factor: 5.091

Review 9.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

Review 10.  Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.

Authors:  Nrupa Borkar; Huiling Mu; René Holm
Journal:  Asian J Pharm Sci       Date:  2017-12-06       Impact factor: 6.598
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.